Acquisition valued at $2.9 billion.
Soleno Therapeutics has an approved medicine for a rare disease.
The rare disease causes insatiable hunger.
Strategic angle: Neurocrine Biosciences is acquiring Soleno Therapeutics for $2.9 billion, gaining access to a treatment for a rare disease linked to insatiable hunger.
Acquisition valued at $2.9 billion.
Soleno Therapeutics has an approved medicine for a rare disease.
The rare disease causes insatiable hunger.